Following these promising results, the combination of this vaccine with nimotuzumab, a humanized anti-EGFR mAb, is being evaluated in a phase I/II trial on patients with metastatic TNBC and non-small cell lung cancer (RPCEC00000218 and RPCEC00000270, respectively, Cuban Public Registry of Clinical Trials), with the primary outcome of OS, and secondary outcomes of safety, OR, PFS, QoL, and immune response. Here, EGFR is linked to non-small cell lung carcinoma.